We are live on ! Find out more
Lazard Asset Management

Lazard Asset Management Portfolio holdings

AUM $60.8B
1-Year Est. Return 22.47%
This Fund
S&P 500
This Quarter Est. Return
+0.1%
1 Year Est. Return
+22.47%
3 Year Est. Return
+62.53%
5 Year Est. Return
+77.87%
10 Year Est. Return
+305.76%
AUM
$68.4B
AUM Growth
-$6.42B
Cap. Flow
-$9.95B
Cap. Flow %
-14.55%
Top 10 Hldgs %
25.74%
Holding
2,605
New
281
Increased
825
Reduced
894
Closed
234

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$433M
2
MRK icon
Merck
MRK
+$286M
3
J icon
Jacobs Solutions
J
+$265M
4
EFX icon
Equifax
EFX
+$253M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$240M

Sector Composition

Rank Sector Weight
1 Technology 26.04%
2 Financials 14.64%
3 Healthcare 12%
4 Industrials 10.54%
5 Consumer Discretionary 9.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
GOOD
1826
Gladstone Commercial Corp
GOOD
$593M
$42K ﹤0.01%
+2,627
New +$43.5K
VHI icon
1827
Valhi
VHI
$388M
$42K ﹤0.01%
1,830
+397
+28% +$11.8K
ADM icon
1828
Archer Daniels Midland
ADM
$37.4B
$41K ﹤0.01%
822
+11
+1% +$595
PPLI
1829
People Inc
PPLI
$3.29B
$41K ﹤0.01%
1,164
-4,957
-81% -$199K
NTST
1830
NETSTREIT Corp
NTST
$2.15B
$41K ﹤0.01%
+2,958
New +$46K
ORN icon
1831
Orion Group Holdings
ORN
$418M
$41K ﹤0.01%
+5,676
New +$41K
RPC
1832
Ridgepost Capital
RPC
$978M
$41K ﹤0.01%
+3,329
New +$40.6K
ARTNA icon
1833
Artesian Resources
ARTNA
$352M
$40K ﹤0.01%
1,283
+120
+10% +$4.11K
CTBI icon
1834
Community Trust Bancorp
CTBI
$1.43B
$40K ﹤0.01%
764
-49
-6% -$2.68K
MITK icon
1835
Mitek Systems
MITK
$800M
$40K ﹤0.01%
+3,631
New +$33.9K
NRIX icon
1836
Nurix Therapeutics
NRIX
$2.61B
$40K ﹤0.01%
2,155
LUMN icon
1837
Lumen
LUMN
$6.27B
$39K ﹤0.01%
7,498
+7,307
+3,826% +$50.4K
NVAX icon
1838
Novavax
NVAX
$1.27B
$39K ﹤0.01%
4,934
-3,718
-43% -$35.8K
UMH
1839
UMH Properties
UMH
$1.29B
$39K ﹤0.01%
2,087
-132
-6% -$2.52K
FOR icon
1840
Forestar Group
FOR
$1.51B
$38K ﹤0.01%
+1,483
New +$44.4K
JOE icon
1841
St. Joe Company
JOE
$3.7B
$38K ﹤0.01%
+852
New +$44.1K
NPCE icon
1842
Neuropace
NPCE
$467M
$38K ﹤0.01%
3,407
-20
-0.6% -$174
RBLX icon
1843
Roblox
RBLX
$25.9B
$38K ﹤0.01%
660
+10
+2% +$503
RSKD icon
1844
Riskified
RSKD
$701M
$38K ﹤0.01%
+8,199
New +$38K
CVNA icon
1845
Carvana
CVNA
$76.4B
$37K ﹤0.01%
925
-15,340
-94% -$689K
ASC icon
1846
Ardmore Shipping
ASC
$672M
$36K ﹤0.01%
+2,986
New +$40.6K
PAGP icon
1847
Plains GP Holdings
PAGP
$4.96B
$36K ﹤0.01%
1,971
+22
+1% +$409
ENZ
1848
DELISTED
Enzo Biochem, Inc.
ENZ
$36K ﹤0.01%
50,453
AIR icon
1849
AAR Corp
AIR
$5.91B
$35K ﹤0.01%
584
-5,671
-91% -$363K
FPI
1850
Farmland Partners
FPI
$431M
$35K ﹤0.01%
3,027
-191
-6% -$2.24K

Similar funds

Lazard Asset Management's Q4 2024 Portfolio in Review

As of Q4 2024, Lazard Asset Management held 2,605 positions worth $68.4B, down 8.6% from $74.8B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Lazard Asset Management withdrew a net $9.95B in Q4 2024, closing 234 positions and reducing 894 holdings. Its most notable exit was Atlantica Sustainable Infrastructure plc Ordinary Shares, an estimated $210M position sold in full.

By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 26% a quarter earlier, followed by Financials and Healthcare.

Against the trend, Lazard Asset Management opened a new position in Vaxcyte worth $39.8M.

  • Lazard Asset Management's largest Q4 2024 buy was Vaxcyte: 486,764 shares worth $39.8M.
  • Lazard Asset Management added most to Eli Lilly in Q4 2024, an estimated $433M increase.
  • Lazard Asset Management's biggest Q4 2024 reduction was Microsoft, cutting an estimated $710M.
  • Lazard Asset Management fully exited Atlantica Sustainable Infrastructure plc Ordinary Shares in Q4 2024, selling an estimated $210M.
  • Lazard Asset Management's ten largest holdings make up 26% of its $68.4B portfolio in Q4 2024.
  • Lazard Asset Management opened 281 new positions and closed 234 in Q4 2024.
  • Lazard Asset Management's portfolio value fell 8.6% quarter-over-quarter to $68.4B.

Based on Lazard Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.